OSI Pharma reiterated by Merrill at buy

OSI Pharmaceuticals was reiterated by Merrill Lynch analyst Eric Ende at a buy rating with a price target on the stock of $56 per share following second-quarter results. Merrill said further European approval of its lung cancer drug Tarceva, in development with Genentech Inc., could provide upside. OSI Pharma shares Thursday declined $1.03, or 2.34%, to close at $42.95 on volume of 1,043,628 shares versus the three-month running average of 1,426,760 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.